Copy neutral LOH of FANC F gene: implication on differential diagnosis and treatment of aplastic anemia: letter
D. Jain,Ritesh Kumar,B. K. Malik,V. Raina
DOI: https://doi.org/10.1111/j.1600-0609.2012.01834.x
2012-08-03
European Journal Of Haematology
Abstract:To the Editor: Management of aplastic anemia (AA) is, to an extent, based on the differential diagnosis whether acquired or constitutional (1). Fanconi anemia (FA) is the most common cause of constitutional AA. Chromosomal Breakage Study (CBS) using Mitomycin-C is widely used for differential diagnosis of AA. The interpretation of results, however, may be complicated by mosaicism and heterozygosity for one of the FA gene (2). Failure to detect FA may lead to inappropriate treatment for the individual patient (3). Molecular testing using SNP arrays provides efficient identification and discovery of aberrant region and variation at single base (4). We hereunder summarize a case wherein the SNP array was crucial in determining the diagnosis and treatment modality for FA. A 19-yr-old man presented with severe pancytopenia and was diagnosed to have AA. Initially, as the CBS was negative for excessive breakages and PNH was excluded, an acquired etiology was considered. Allogenic stem cell transplant was recommended but was not feasible due to unavailability of HLA-matched sibling and lack of resources for a matched unrelated transplant. Immuno-suppressive therapy (IST) was opted for as the first line of treatment. When monitored, with standard guidelines (5), the patient failed to respond to both horse anti-thymocytic globulin (ATG; Atgam; Pfizer Inc., New York, NY, USA) and rabbit ATG; Thymoglobuline; Genzyme Co., Cambridge, MA, USA). Keeping the failure with IST and limitation of CBS in mind, the patient was investigated on array-based cytogenetic using HumanCytoSNP-12v2-1 chip (Illumina, Inc., San Diego, CA, USA). The test interference was done using Karyostudio software (Illumina, Inc., San Diego, CA, USA). The results were tallied with DECIPHER (http://decipher.sanger. ac.uk), NCBI Genome build 36.1, and database of Genomic variants (http://projects.tcag.ca). The patient showed copy neutral loss of heterozygosity (LOH) of approximately 11Mb on chromosome #11. The aberration possessed FANC F gene. Confirmation of the aberration was performed using mutation analysis of the FANC F gene (6). The pathogenic mutation c.484-485delCT was identified. However, the zygosity point could not be addressed as the parental samples were not available. Owing to the proven constitutional etiology of the disease, allogenic peripheral blood hematopoietic stem cell transplant was performed with 5/6 class-I, HLA matched donor, to which the patient responded very well. Lack of physical abnormalities does not rule out the diagnosis of FA, as these are present in only 60–75% of affected individuals (2). Although stem cell transplantation (SCT) is the treatment of choice for patients with AA, regardless of etiology, it requires a modified conditioning for patients with FA. IST plays no role in the management of FA and in fact may lead to adverse effects (3). Hence, determining the definitive etiology becomes significant for treatment for AA. The cost-effectiveness of the CBS makes it the first line investigation for differential diagnosis of AA in India (7). In our patient, the LOH represents homozygous allelic state of the mutation, which might have arisen because of autozygosity or a gene conversion event. As pedigree of the patient does not indicate any consanguinity, autozygosity appears to be an unlikely mechanism. The gene conversion event seems to be a more plausible explanation of the origin of the aberration, as such events are known to occur owing to error in meiotic and/or mitotic cell division (8). This might have given rise to mosaicism, thus explaining the negative chromosome breakage test in the present case (2). As a first-tier test, sequence analysis for FA is complicated by the number of genes to be analyzed, the large number of possible mutations in each gene, the presence of large insertions or deletions in some genes, and the large size of many of the FA-related genes. (1, 2) Cytogenetic microarrays (CMA) as a first-tier test has 12.2% higher diagnostic yield than that of a G-banded karyotype (9). The FANC F gene aberration accounts for 8% of patients with FA (10). Stem cell transplant was performed in this patient as it is the only curative therapy for hematologic manifestations of FA (1, 2). We hereby conclude that in conjunction with the CBS, newer approaches like CMA should be used for etiological determination of AA. Better prognosis with SCT in the present case raises a need of further clinical studies to understand the role of partially HLA-matched SCT over IST in patients affected with constitutional AA.